Project core team member and responsible for translational medicine strategy for Vecabrutinib, a noncovalent BTK inhibitor in clinical development for B-cell malignancies o Developed and executed translational medicine strategy for Phase 1b/2 clinical study: o Characterize patient attributes potentially associated with outcome (NGS, cytogenetics) o Characterize pharmacodynamic activities (serum chemokines and cytokines) o Establish and oversee academic collaborations to better understand BTK inhibitor resistance mechanisms, potential indications and product differentiation o Oversee CRO activities for correlative studies o Site interactions to support correlative studies implementation o Leader of Vecabrutinib Diagnostics/Translational Medicine subteam: identified diagnostics partner and critical path/timing for CDx development (qPCR assay for detection of C481S mutation) o Clinical pharmacodynamic/pharmacokinetic data review o Planning and data review of nonclinical collaborations o Member of Vecabrutinib Core Team to formulate and execute development plan o Author relevant components of regulatory documents (clinical protocols, IB, ICF) o Present results internally at team and board meetings, externally at investigator and investor meetings Project Team Leader and responsible for translational research and nonclinical development strategy for SNS-510, PDK1 inhibitor in IND-enabling program for hematologic and solid tumor cancers o SNS-510 Project Team Leader  Lead cross-functional (nonclinical, translational, clinical, CMC, regulatory) team to IND projected for 2021  Identified CDKN2A-mutated or deleted cancers as sensitive to SNS-510, supporting potential investigation in CDK4/6 inhibitor-resistant breast cancers  Characterized SNS-510 in vitro and in vivo in models of hematologic and solid cancer, gathering key PK/PD and activity data o Present and publish results at scientific congresses, investigator and investor meetings

In September 2013 Astex was acquired by Otsuka Pharmaceutical Co., Ltd.Translational Pharmacology lead for:• INQOVI (ASTX727), an oral hypomethylating agent combining 5-aza-2'-deoxycytidine (decitabine) and cedazuridine, a novel cytidine deaminase inhibitor, approved by FDA for intermediate and high-risk MDS and CMML patients. • Guadecitabine (SGI-110), a second-generation DNA hypomethylating agent (dinucleotide of decitabine and 2’-deoxyguanosine) from Phase 1 through multiple Phase 3 studies; • Tolinapant (ASTX660), an oral cIAP and XIAP inhibitor currently in Phase 2 for the treatment of T-cell lymphoma; • SGI-1776, first PIM kinase inhibitor to enter clinical development in Phase 1 for refractory prostate cancer and relapsed/refractory non Hodgkin's lymphoma; • Amuvatinib (MP-470), an oral TKI and Rad51 inhibitor that progressed until phase 2 for SCLC in combination with Carbo/Etoposide o Initiated and championed the study of HMAs as immunomodulatory agent o Established interactions with KOL that led to numerous IST o Supervised remotely 2 translational R&D lab scientists o Translational Team Meeting Chair for a company-wide UK/US team to review translational research and development strategy o Implemented and provided oversight of correlative studies at internal, academic and CRO labs o Interacted with data management and biometrics departments to implement data transfer plans and data analysis suitable for regulatory documents o Managed and maintained a continuous exchange of information with academic collaborators, CROs, and internal lab scientists to optimize assays, generate data and deliver results to drive the clinical study progress and presentations at scientific meetings (ASH, AACR, ASCO, etc) o Supervised the validation and execution of a biomarker assay (LINE-1) in a CLIA controlled environment o Authored relevant sections of clinical study protocols, investigator brochures, clinical study reports

In September 2011 SuperGen, Inc. acquired Astex Therapeutics Limited and the name was changed to Astex Pharmaceuticals, Inc.

Pharmacology representative and core team member for SNS-314, an Aurora Kinase A+B inhibitor, the first molecule from Sunesis drug discovery program to enter Phase 1 for solid tumors. Managed and directed the translational science aspects for the clinical development (Phase I) of SNS-314 in collaboration with Sunesis clinical scientists and external clinical investigators. Profiled SNS-032, a CDK 2, 7 and 9 inhibitor that was tested in phase I in hematological malignancies (CLL and MM). Managed job duties and supervised studies of 1 Scientist, 2 Staff Research Associates and 1 Research Associate

Pharmacology lead and core team member for : HSP990, a novel oral HSP90 inhibitor that progressed until phase 1 for advanced solid malignancies; Tezacitabine, an anticancer nucleoside analog that progressed until phase 2 for advanced esophageal and colorectal cancer. o Designed, and coordinated studies on tumor xenograft models to evaluate PK/PD and efficacy of small molecule drug candidates. o Identified and developed target-dependent tumor models, PD markers and laboratory assays for the characterization of novel proprietary oncology therapeutics. o Pharmacology representative to cross-functional Hsp90 team o Managed job duties and supervised studies of Research Specialist and Research Associate. o Wrote clinical protocol section on PD evaluation of tezacitabine drug metabolites in human PBMCs. o Investigated tezacitabine-induced DNA damage in tissue culture, ex-vivo and clinical samples. o Regularly presented project updates to departmental meetings, project team meetings and Research Management Team. o Evaluated in-licensing opportunities.

o Identified new targets and products for DNA repair inhibitor based cancer therapy. Developed screening methods to identify and characterize small molecules with potential clinical interest. o Supervised a research associate maintaining a panel of human cancer cell lines. o Presented company technology at business and academic meetings, and to potential investors and corporate partners. o Established and managed external collaborative research projects.